Updated Phase 3 data analyzing the Pfizer-BioNTech COVID-19 vaccine up to six months after second vaccination showed it was 91.3% effective overall and 100% effective versus severe disease.
The vaccine candidate had an 85% overall efficacy at preventing severe disease 28 days after vaccination and a 66% overall efficacy rate in preventing moderate-to-severe COVID-19.
Valneva SE, has initiated a Phase 1/2 clinical study for its inactivated, adjuvanted COVID-19 vaccine candidate, VLA2001.
The FDA approved an Abbreviated New Drug Application for Lupin Ltd’s albuterol sulfate inhalation aerosol 90 mcg, a generic for Teva’s ProAir HFA.
Read More
The drug, Kaftrio, produced by Vertex Pharmaceuticals, will be available through the NHS to many who have cystic fibrosis.
Read More
The COVID-19 vaccine, known as ‘Sputnik V’ and developed by the Gamaleya Research Institute in Moscow, has reportedly been tested in just 76 humans.
Read More
Two doses of Moderna’s experimental COVID-19 vaccine induced robust immune responses and rapidly controlled the coronavirus in the upper and lower airways of rhesus macaques exposed to SARS-CoV-2.
Read More
The first clinical results for remdesivir’s effectiveness on severe COVID-19 demonstrated clinical improvements but remain unclear because no control group was included in the study.
Read More
The FDA has approved the Fluzone High-Dose Quadrivalent (Influenza Vaccine) for adults 65 years of age and older. The vaccine will be available for fall 2020.
Read More
The European Medicines Agency has advised that Adempas (riociguat) should not be prescribed to patients with pulmonary hypertension (PH) associated with idiopathic interstitial pneumonia.
Read More
The results from an ongoing Phase 3 study supports the long-term use of riociguat in patients with chronic thromboembolic pulmonary hypertension (CTEPH).
Read MoreCanada’s public Ontario Health Insurance Plan (OHIP) is now covering the breakthrough cystic fibrosis drug Kalydeco, a decision that came after public pressure to cover the drug.
Read MoreThe drug, ricoiguat, could prove effective as a treatment option for patients with PAH.
Read More